Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 2 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 2 | 5 |
| 2005 | 5 | 2 | 7 |
| 2006 | 9 | 2 | 11 |
| 2007 | 7 | 1 | 8 |
| 2008 | 13 | 0 | 13 |
| 2009 | 9 | 3 | 12 |
| 2010 | 10 | 1 | 11 |
| 2011 | 13 | 5 | 18 |
| 2012 | 7 | 1 | 8 |
| 2013 | 10 | 1 | 11 |
| 2014 | 15 | 1 | 16 |
| 2015 | 16 | 4 | 20 |
| 2016 | 10 | 3 | 13 |
| 2017 | 14 | 5 | 19 |
| 2018 | 12 | 5 | 17 |
| 2019 | 22 | 5 | 27 |
| 2020 | 21 | 8 | 29 |
| 2021 | 14 | 8 | 22 |
| 2022 | 5 | 11 | 16 |
| 2023 | 1 | 5 | 6 |
| 2024 | 5 | 4 | 9 |
| 2025 | 16 | 1 | 17 |
| 2026 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial. BMJ Open. 2026 Apr 24; 16(4):e112623.
-
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors. Cancer Chemother Pharmacol. 2026 Mar 14; 96(1).
-
The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial. Cancer Res Commun. 2026 Mar 01; 6(3):706-713.
-
Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicity. Int Immunopharmacol. 2026 Apr 15; 175:116222.
-
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study. Lancet Digit Health. 2026 Feb; 8(2):100952.
-
Accelerating Drug Development in Hormone-Na?ve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. Clin Cancer Res. 2026 Feb 04; 32(3):479-488.
-
Evaluating Vulnerable Elders Survey-13 and FIL Geriatric Assessment in Older Adults With Aggressive Lymphomas. J Natl Compr Canc Netw. 2026 Feb; 24(2).
-
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. J Immunother Cancer. 2026 Jan 14; 14(1).
-
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers. J Immunother Cancer. 2025 Dec 21; 13(12).
-
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). J Clin Oncol. 2026 Jan 20; 44(3):153-163.